Home
overview

The conference listed on this page was held in 2008. For information on the 2010 conference go to www.metabolicdisorders.co.uk

Emerging Therapeutic Strategies for Metabolic Disorders

 


Metabolic diseases affect millions of sufferers worldwide and are having an increasingly negative impact upon the health of our society as a whole. Diabetes affects approximately 246 million people worldwide and is increasing; the IDF predicts 380 million diabetics by 2025. The Global Diabetes drug treatment market was valued at over $21 billion in 2006 and the market is still expanding rapidly due to the high prevalence of diabetes and lifestyle changes. According to recent figures, type II diabetes affects more than 90% of diabetic people whilst those meeting the criteria set for obesity reaches 300 million respectively.

The SMi Group would like to announce its 2nd Metabolic Diseases Conference designed specifically to uncover the latest market trends, challenges and emerging therapies.

Take a closer look at key disease specific drugs on track towards regulatory approval and market release. Learn how to overcome challenges in developing novel metabolic therapies and discover what is really expected in a new product application and how to achieve it.

 

 


    Dr Michael Mark, Vice President, Metabolic Diseases Research, Boehringer Ingelheim
    Dr Michael R. Hanley, Vice President of Discovery Research, Amylin Pharmaceuticals
    Dr Douglas Greene, Chief Medical Officer, Sanofi-Aventis
    Professor Jon Arch, Professional Research Fellow and Deputy Director, Metabolic Research, University of Buckingham and former Director, Drug Discovery, GlaxoSmithKline
    Dr Michael Trautman, Medical Fellow, Clinical Investigations, Eli Lilly
    Dr Brian Hubbard, Senior Director, Atherosclerosis, Merck
    Dr John H, Johnson, Senior Director, Worldwide Business Development, Pfizer
    Professor David Heal, Director, Renasci
    Dr Johannes Zanzinger, Director, Global Licensing Metabolic Diseases, Boehringer Ingelheim
    Dr Timothy Herpin, Director, Metabolic Disease Licensing, Bristol-Myers Squibb
    Dr Manfred Ganz, Associate Professor of Clinical Management , Campus Biomedico, University of Rome, Italy
  • Dr Uwe Gudat, Global Brand Medical Director, Dyslipidemia & Diabetes, Novartis
  • Dr Tomas Landh, Director, Novo Nordisk
  • Dr  Alexei Kharitonenkov, BioTechnology Discovery Research, Eli Lilly
  • Dr Shankari Mylvaganam, Vice President of Research, Sapient Discovery
  • Dr Farzaad Abdi-Dezfuli, Partner, Sarsia Seed Management AS
  • Dr Eric Tomlinson, President & Chief Executive Officer, Altea Therapeutics Corporation
  • Dr Mike Cawthorne, Director of Metabolic Research, University of Buckingham

This year’s conference cover:

  • Emerging therapeutics in the metabolic disease market
  • The future of drug discovery for metabolic diseases
  • Current and future targets for next generation drugs in order for treating diabetes and obesity
  • Regulatory developments and the licensing landscape
  • Patient adherence issues and solutions
  • Translational medicine
  • Many metabolic links to symptomatic and pathophysiological manifestations of AD
  • Kinase inhibitors in the treatment of metabolic diseases
  • Fatty acids and fatty acid receptors
  • Obesity as an inflammatory disease: how to treat
  • Comparing DPP4 inhibitors with GLP-1 mimetics
  • Nonpeptide GLP-1 agonists
  • New generations of PPARs

 


 

You will benefit from attending this event if you are:

Vice President, Director, Manager or Supervisor from within the pharmaceutical or biotech industry with responsibilities in the following areas:
 
 
 
  • Drug Discovery
  • Metabolic diseases
  • Preclinical Development
  • Cardiovascular Disease
  • Research & Development
  • Clinical Science
  • Marketing
  • Endocrinology & Metabolism
  • ADME
  • DMPK
  • Pharmacokinetics
  • Drug Metabolism
  • Toxicology
  • Computational Chemistry
  • Diabetes & Obesity
  • Molecular Modelling
  • Cheminformatics
  • Drug Design
  • Biomolecular Screening
  • Physical Chemistry
  • Medicinal Chemistry
  • Lead Optimisation
  • Structural Biologists

 
 

For Speaking opportunities please contact Simon Curtis at jjouret@smi-online.co.uk
For Sponsorship opportunities please contact Alia Malick at amalick@smi-online.co.uk


 

 
 
About the conference Venue:


 

 
The Copthorne Tara Hotel is located in a quiet corner of the Royal Borough of Kensington & Chelsea.  Ideal for exploring London, whilst it is easily accessible from the M4 with Heathrow Airport only 30 minutes drive. It is located very conveniently near High Street Kensington Tube Station on the District and Circle London Underground Lines.  The hotel boasts an impressive 833 air-conditioned bedrooms; these include Standard rooms, Club rooms on the upper floors which offer city views and access to a private lounge, adapted rooms for the disabled traveller, suites and business apartments.

 

 

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Jon Arch

Jon Arch, Professorial Research Fellow & Deputy Director, Metabolic Research, University of Buckingham
View Bio

9:10 EMERGING THERAPEUTICS IN THE METABOLIC DISEASE MARKET

Johannes Zanzinger

Johannes Zanzinger, Director, Global Licensing Metabolic Diseases, Boehringer Ingelheim

  • Current and upcoming therapies for T2D
  • Profiling the market and future medical needs for the treatment of Metabolic Diseases
  • Chances and risks of novel approaches that target various risk factors simultaneously
  • How to overcome the challenges in developing novel  'cardio-metabolic' therapies
  • 9:50 EXPLORING THE METABOLIC PEPTIDOME FOR NOVEL THERAPEUTICS

    Michael Hanley

    Michael Hanley, Chief Scientific Officer, Amylin Pharmaceuticals

  • We have built a proprietary bioactive peptide library which constitutes a rich resource for metabolic drug discovery 
  • Library-wide screens have identified multiple novel peptides with potential utility as diabetes and obesity treatments 
  • We have implemented a strategy, Integrated Neurohormonal Therapy,  which captures the superior drug attributes of combination drugs 
  • Parent peptides are rarely the drug candidates, so targeted pharmaceutical property improvement is key to moving a candidate to a potential product  
  • 10:30 Morning Coffee

    11:00 BASAL INSULIN TRANSDERMAL PATCH

    Eric Tomlinson

    Eric Tomlinson, President & Chief Executive Officer, Altea Therapeutics Corporation
    View Bio

  • Sustained and constant insulin delivery at therapeutic levels
  • Potential for lower risk of hypoglycemia
  • Efficient delivery of insulin
  • Potential for convenient storage at room temperature
  • Anticipated greater patient compliance and earlier adoption of insulin in diabetes management
  • 11:40 DEVELOPMENTS IN THE LICENSING LANDSCAPE

    Timothy Herpin

    Timothy Herpin, Director, Strategy Transaction Group, Bristol-Myers Squibb

  • Licensing landscape
  • Deal making trends
  • Financing and strategic development of diabetes biotech companies
  • 12:20 Networking Lunch

    13:50 SEE THE FULL PICTURE: VALUE AND IMPACT OF GLYCEMIC VARIABILITY (GV) IN DIABETES MELLITUS

    Manfred Ganz

    Manfred Ganz, Associate Professor of Clinical Management, Campus Biomedico, University of Rome

  • GV is more than just HbA1c
  • importance of "peaks and valleys"
  • how to measure: 7-point SMBG or Continuous Monitoring?
  • GV as independant risk marker for cardiovascular complications?
  • 14:30 THERAPEUTIC USE OF THE INCRETIN SYSTEM IN TYPE 2 DIABETES

    Michael Trautmann

    Michael Trautmann, Medical Fellow - Global Exenatide Team, Eli Lilly & Company
    View Bio

  • The incretin effect in normal physiology and Type 2 Diabetes
  • Effects of GLP-1
  • Therapeutic approaches: GLP-1 analogs and DPP IV inhibition
  • Exenatide: The first incretin mimetic
  • Clinical trial results
  • Future developments
  • 15:10 Afternoon Tea

    15:30 SATISFYING THE REGULATORS' DEMANDS FOR ANTI-OBESITY DRUGS

    Jon Arch

    Jon Arch, Professorial Research Fellow & Deputy Director, Metabolic Research, University of Buckingham
    View Bio

  • Regulators' expectations of anti-obesity drugs.
  • How well do current drugs meet these targets?
  • Will drugs and combinations of drugs in development do better?
  • Novel approaches that target fat metabolism may offer most metabolic benefit.
  • 16:10 DPP 4 INHIBITORS: FEATURING BI 1356 - BI'S PHASE III DPP 4 INHIBITOR

    Michael Mark

    Michael Mark, Vice President, Metabolic Diseases Research, Boehringer Ingelheim

  • DPP 4 inhibition as treatment for type 2 diabetes          
  • Comparison of DPP 4 inhibitors with GLP-1 analogs      
  • BI 1356 (proposed trade-name ONDERO) - profile of a novel DPP 4 inhibitor   
  • 16:50 PANEL DISCUSSION

    Wick Johnson

    Wick Johnson, Senior Director, Worldwide Business Development, Pfizer
    View Bio

    Timothy Herpin

    Timothy Herpin, Director, Strategy Transaction Group, Bristol-Myers Squibb

    Johannes Zanzinger

    Johannes Zanzinger, Director, Global Licensing Metabolic Diseases, Boehringer Ingelheim

    Farzaad Abdi-Dezfuli

    Farzaad Abdi-Dezfuli, Partner, Sarsia Seed Management

    Mike Cawthorne

    Mike Cawthorne, Director of Metabolic Research, The University of Buckingham
    View Bio

    17:30 Chairman’s Closing Remarks and Close of Day One

    8:30 Registration & Coffee

    9:00 Chairman's Opening Remarks

    Douglas Greene

    Douglas Greene, Senior Vice President & Chief Medical Officer, Sanofi-Aventis

    9:10 DEVELOPMENTS IN THERAPEUTIC PROTEINS FOR DIABETES CARE

    Tomas Landh

    Tomas Landh, Director, Novo Nordisk

    • Diabetes outlook
    • Current developments and pipelines in the field of diabetes care
    • Modern insulins
    • New polypeptide therapeutics
    • Alternative drug delivery initiatives and formulations
    • Key challenges facing the industry
    • Important patient needs
    • Outlook on the future protein therapetuics and protein drug delivery for treating diabetes

    9:50 STRUCTURE BASED DRUG DESIGN: EXPERIENCES OF A CRYSTALLOGRAPHER ON A METABOLIC DISEASES TARGET

    Shankari Mylvaganam

    Shankari Mylvaganam, Vice President, Co-Founder, Sapient Discovery

  • X-ray crystallography is now an integral part of lead discovery and optimization
  • A case study will be presented on a metabolic diseases target using an SBDD platform
  • The crucial feedback from crystallography for the lead optimization will be highlighted
  • Applications to other ongoing programs will be outlined
  • 10:30 Morning Coffee

    11:00 THE “METABOLIC/OBESITY EPIDEMIC,” A DOUBLE-EDGED SWORD GENERATING GLOBAL MEDICAL NEED AND STRIKING REACTIVE REGULATORY FEAR

  • Demographic and nutritional trends increase the depth and breadth of metabolic illness
  • Increasing scientific potential to decipher and ameliorate complex diseases
  • Growing political disillusion and professional mistrust of the biomedical and healthcare delivery community
  • Regulatory focus on absolute rather than relative risk or risk/benefit
  • Beyond the precautionary principle:  Risk management in a risk aversive environment for novel treatment modalities of widespread “non-life-threatening disease
  • Douglas Greene

    Douglas Greene, Senior Vice President & Chief Medical Officer, Sanofi-Aventis

    11:40 GLYCEROLIPID ACETYLTRANSFEREASES AND METABOLIC DISORDERS

  • Triglyceride and phospholipid metabolic pathways
  • Emerging players and hypothesis
  • Relevance to diseases and the opportunities to intervene
  • Guoqing Cao

    Guoqing Cao, Research Advisor, Lilly Research Laboratories USA

    12:20 Networking Lunch

    13:50 PATIENT ADHERENCE ISSUES AND SOLUTIONS

    Uwe Gudat

    Uwe Gudat, Global Brand Medical Director, Dyslipidemia & Diabetes, Novartis

  • Adherence problems resulting in glycemic control difficult to attain
  • Reducing diabetes by effective adherence techniques
  • Factors underlying the scope of the adherence problem
  • Concepts of compliance and adherence
  • Adopting a more collaborative model of care emphasizing patient autonomy and choice
  • 14:30 ARRY-588 AND ARRY-403, NOVEL GLUCOKINASE ACTIVATORS WITH POTENT GLUCOSE-LOWERING ACTIVITY IN ANIMAL MODELS OF TYPE 2 DIABETES MELLITUS

    Steven Boyd

    Steven Boyd, Director, Array BioPharma

  •  Potent  in vitro activation of glucokinase, a key regulator of glucose metabolismGood drug-like properties (permeability, solubility, low potential for drug-drug interactions, orally bioavailable)
  • Demonstate dose-dependent Acute anti-hyperglycemic efficacy in normal mice (oral glucose tolerance test)
  • Effiacious in mouse models of type 2 diabetes (acute and sub-chronic dosing)
  • No increase in weight relative to controls, no adverse effect on serum cholesterol or triglycerides
  • 15:10 Afternoon Tea

    15:40 EMERGING CNS APPROACHES TO OBESITY TREATMENT

    David Heal

    David Heal, Director, RenaSci
    View Bio

  • The most recent drugs approved for obesity treatment and its related co-morbidities i.e. the SNRI, sibutramine, and the cannabinoid CB1 antagonist, rimonabant, decrease food intake by central mechanisms
  • Sceptism whether the next generation of centrally-acting drugs will deliver the degree of greater efficacy combined with improved safety/tolerability that is an absolute requirement for success in this therapeutic indication
  • Some of the most interesting new CNS approaches will be reviewed such as 5-HT6 receptor ligands, 5-HT2C receptor agonists, noradrenalinine reuptake inhibitor + 5HT1A agonist compounds and fixed-dose combination therapies
  • 16:20 VENTURE CAPITAL AND THE FUNDING OF EMERGING THERAPEUTICS FOR TREATMENT OF METABOLIC SYNDROME ABNORMALITIES

    Farzaad Abdi-Dezfuli

    Farzaad Abdi-Dezfuli, Partner, Sarsia Seed Management

  • Prospect procurement and risk-management - affiliation of big pharma with venture capital
  • Financing and strategic development of companies in the field - private vs. corporate venture
  • Innovative technologies/compounds under development
  • Value offering:  novelty versus more of the same but better - prospect source: academia vs. companies
  • Partnership deals between big pharma  and VC backed small biotech - licensing versus acquisition and recent collaborations in the disease cluster area
  • 17:00 Chairman’s Closing Remarks and Close of Conference

    +

    Workshops

    Metabolic Diseases: The Opportunity, Drug Discovery Approaches and Case Studies
    Workshop

    Metabolic Diseases: The Opportunity, Drug Discovery Approaches and Case Studies

    Copthorne Tara Hotel
    23rd September 2008
    London, United Kingdom

    Copthorne Tara Hotel

    Scarsdale Place
    Kensington
    London W8 5SR
    United Kingdom

    Copthorne Tara Hotel

    The Copthorne Tara Hotel London Kensington is an elegant contemporary four-star hotel in prestigious Kensington, located just a two minutes walk from High Street Kensington underground station, making exploring easy. The hotel offers well-appointed and comfortable guest rooms combining Standard, Superior and Club accommodation. Club rooms offer iconic views over the city and include Club Lounge access for complimentary breakfast and refreshments. Guests can sample the authentic Singaporean, Malaysian and Chinese cuisine at Bugis Street, traditional pub fare at the Brasserie Restaurant & Bar or relax with a delicious drink at West8 Cocktail Lounge & Bar.

    The Copthorne Tara Hotel boasts 745 square meters of flexible meeting space, consisting of the Shannon Suite and the Liffey Suite, ideal for hosting conferences, weddings and social events. Facilities include access to the business centre 24 hours a day, fully equipped fitness room, gift shop, theatre desk and Bureau de Change. With ample onsite parking outside the London congestion charge zone and excellent transport links via Heathrow Airport, the hotel is the perfect location for business or leisure stays. The hotel is within close proximity to the shops of High Street Kensington, Knightsbridge and Westfield London, Olympia Conference Centre, Royal Albert Hall, Kensington Palace and Hyde Park.

     

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.